AIDS

1. READY EA, Patterson C, Gibbons S, Yoong D, et al
   Assessing ChatGPT's capability in understanding and reporting antiretroviral therapy drug-drug interactions (ACCURATE-DDI).
   AIDS. 2026 Apr 13. doi: 10.1097/QAD.0000000000004522.
   

   >> Share

   
   

   
   Ann Intern Med

2. ALBALOUL H, Nemer A, Saini N, Schuster MG, et al
   Infectious Diseases: What You May Have Missed in 2025.
   Ann Intern Med. 2026 Apr 14:e2600983. doi: 10.7326/ANNALS-26-00983.
   

   >> Share

   
   

   
   Clin Infect Dis

3. HOFFMAN R, Brummel S, Pinilla M, Malonga G, et al
   Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIV.
   Clin Infect Dis. 2026 Apr 13:ciag245. doi: 10.1093.
   

   >> Share

   
   
4. WYNCOLL J, Kamolrattana R, Archary M, Mujuru HA, et al
   Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial.
   Clin Infect Dis. 2026 Apr 10:ciag232. doi: 10.1093.
   

   >> Share

   
   

   
   HIV Med

5. FOX D, Slim J, Overton ET, Doblado-Maldonado A, et al
   Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.
   HIV Med. 2026 Apr 16. doi: 10.1111/hiv.70237.
   

   >> Share

   
   
6. HENDERSON M, Dutey-Magni P, Herrera C, Stohr W, et al
   Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART.
   HIV Med. 2026 Apr 16. doi: 10.1111/hiv.70236.
   

   >> Share

   
   

   
   J Infect Dis

7. WARRIER L, Saito A, Graham JB, Swarts JL, et al
   Initiation of oral pre-exposure prophylaxis associated with changes in genital tract T cell phenotypes in women exposed to HIV.
   J Infect Dis. 2026 Apr 9:jiag204. doi: 10.1093.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share